US25056L1035 - Common Stock
DESIGN THERAPEUTICS INC
NASDAQ:DSGN (4/29/2024, 7:00:01 PM)
After market: 3.72 0 (0%)3.72
-0.06 (-1.59%)
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. The company is headquartered in Carlsbad, California and currently employs 57 full-time employees. The company went IPO on 2021-03-26. The firm is focused on research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company’s lead product candidate is Friedreich ataxia (FA). Its second product candidate is Fuchs Endothelial Corneal Dystrophy (FECD). The company is also advancing its GeneTAC program to address other serious nucleotide repeat-driven monogenic diseases. Its FA is a devastating monogenic, autosomal recessive progressive disease. The FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD. Its Myotonic Dystrophy Type-1 (DM1) is a monogenic, autosomal dominant, progressive neuromuscular disease that affects skeletal muscle, heart, brain, and other organs.
DESIGN THERAPEUTICS INC
6005 Hidden Valley Road, Suite 110
Carlsbad CALIFORNIA 92011
P: 18582934900
CEO: Joao Siffert
Employees: 57
Website: https://www.designtx.com/
DSGN stock results show that Design Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Design Therapeutics (NASDAQ:DSGN) just reported results for the fourth quarter ...
New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by...
Here you can normally see the latest stock twits on DSGN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: